Ascendis Pharma A-S

Yahoo Finance • 8 days ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 9 days ago

StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Guggenheim upgraded StubHub (STUB) to... Full story

Yahoo Finance • 13 days ago

Liberty All-Star® Growth Fund, Inc. April 2026 Monthly Update

BOSTON, May 15, 2026--(BUSINESS WIRE)--Below is the April 2026 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, April 2026 Investment Approach: Fund St... Full story

Yahoo Finance • 19 days ago

Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit

Matisse Capital fully exited its position in Kayne Anderson Energy Infrastructure Fund(NYSE:KYN), selling 222,839 shares for an estimated $2.99 million based on quarterly average pricing, the firm’s May 8, 2026, SEC filing shows. What hap... Full story

Yahoo Finance • 21 days ago

Ascendis Pharma A/S Q1 Earnings Call Highlights

Ascendis Pharma A/S logo Key Points FDA approval of Ascendis's third TransCon product, YUVIWEL, was secured and the therapy launched in early April, already prescribed for more than 60 children across 35+ providers; management plans to p... Full story

Yahoo Finance • 22 days ago

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly T... Full story

Yahoo Finance • last month

Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This Stock

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Ascendis Pharma A/S (NASDAQ:ASND) ranks 9th on this list. The primary catalyst for hedge fund interest in Ascendis Pharma A/S (NASDAQ:ASND) stock... Full story

Yahoo Finance • last month

European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading

European equities traded in the US as American depositary receipts were higher late Wednesday mornin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the “... Full story

Yahoo Finance • last month

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

Ascendis Pharma COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listi... Full story

Yahoo Finance • 2 months ago

Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq

Ascendis Pharma A/S (NASDAQ:ASND) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 8, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced plans to list its ordinary shares directly on The Nasdaq Global Select Market, e... Full story

Yahoo Finance • 2 months ago

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

Ascendis Pharma - Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held - Si... Full story

Yahoo Finance • 2 months ago

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia

- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community - Enhanced improvements in spinal canal dimensions observed with TransCo... Full story

Yahoo Finance • 2 months ago

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially available in the U.S. with revenue no... Full story

Yahoo Finance • 2 months ago

Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial

Ascendis Pharma A/S (NASDAQ:ASND) is one of the 7 Fastest Growing European Stocks to Invest In. On March 17, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced positive Week 52 topline results from the Phase 2 New InsiGHTS trial evaluating... Full story

Yahoo Finance • 3 months ago

Ascendis Wins FDA Approval For Rare Disease Therapy

Ascendis Pharma A/S shares are up during Monday’s premarket session following the FDA’s approval of Yuviwel (navepegritide; developed as TransCon CNP), the first and only once-weekly treatment for children with achondroplasia. FDA Approva... Full story

Yahoo Finance • 3 months ago

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher gr... Full story

Yahoo Finance • 3 months ago

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines(NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on quarterly average pricing, according to its... Full story

Yahoo Finance • 3 months ago

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

On February 17, 2026, Perceptive Advisors reported a buy of Celcuity(NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on quarterly average pricing. What happened Accor... Full story

Yahoo Finance • 3 months ago

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics(NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average pricing. What happened According to a Febru... Full story